Troriluzole - Biohaven Pharmaceutical

Drug Profile

Troriluzole - Biohaven Pharmaceutical

Alternative Names: BHV-4157; FC 4157; trigriluzole; Trigriluzole-Biohaven Pharmaceutical; Troriluzole-hydrochloride

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; National Cancer Institute (USA); Rutgers Cancer Institute of New Jersey
  • Class Antidementias; Antineoplastics; Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Spinocerebellar degeneration
  • Phase II/III Alzheimer's disease; Obsessive-compulsive disorders
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 24 Jul 2018 Phase-II/III clinical trials in Alzheimer's disease in USA (PO) (NCT03605667)
  • 24 Jul 2018 The US FDA approves IND application for a phase II/III trial in Alzheimer’s disease, prior to July 2018
  • 11 Jul 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top